Advertisement

Associations between Antiretroviral Drugs on Depressive Symptomatology in Homogenous Subgroups of Women with HIV

  • 45 Accesses

Abstract

Antiretroviral therapy (ART) is inconsistently associated with depression. These associations may depend on factors such as biological sex, age, and health status. Identifying such factors may help optimize treatment of HIV and depression. We implemented a novel approach to examine interindividual variability in the association between ART agents and depressive symptoms. 3434 women living with HIV (WLWH) from the Women’s Interagency HIV Study (WIHS) were computationally divided into subgroups based on sociodemographic (e.g., age) and longitudinal (from 1995 to 2016) behavioral and clinical profiles (e.g., substance use, HIV RNA, CD4 counts). Five subgroups (n’s ranged from 482 to 802) were identified and characterized as those with: controlled HIV/vascular comorbidities; profound HIV legacy effects; younger women [<45 years of age] with hepatitis C; primarily 35–55 year olds; and poorly controlled HIV/substance use. Within each subgroup, we examined associations between ART agents used over the past 6 months and item-level depressive symptoms on the Center for Epidemiologic Studies Depression Scale. Tenofovir (4 of 5 subgroups) followed by efavirenz, emtricitabine, stavudine, lopinavir, etravirine, nelfinavir, ritonavir, and maraviroc were the most common agents associated with depressive symptoms, although the pattern and directionality varied by subgroup. For example, lopinavir was associated with fewer symptoms among the subgroup with a legacy HIV effect but more symptoms among the subgroup with well-controlled HIV/vascular comorbidities. Unexpectedly, dolutegravir and raltegravir were not associated with depressive symptoms among any subgroup. Findings underscore marked interindividual variability in ART agents on depression in WLWH. Sociodemographic, clinical, and behavioral factors are important determinants of the relationship between ART agents and depressive symptoms in WLWH.

Are antiretroviral agents a risk factor for depressive symptoms in women with HIV? We examined associations between ART-agents and depressive symptoms among similar subgroups of women with HIV from the Women’s Interagency HIV Study. The patterns of associations depended on sociodemographic, clinical, and behavioral characteristics of women.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 99

This is the net price. Taxes to be calculated in checkout.

Fig. 1

References

  1. Abers MS, Shandera WX, Kass JS (2014) Neurological and psychiatric adverse effects of antiretroviral drugs. CNS Drugs 28:131–145

  2. Adimora AA, Ramirez C, Benning L, Greenblatt RM, Kempf MC, Tien PC, Kassaye SG, Anastos K, Cohen M, Minkoff H, Wingood G, Ofotokun I, Fischl MA, Gange S (2018) Cohort profile: the Women's Interagency HIV study (WIHS). Int J Epidemiol 47:393–394i

  3. Aljassem K, Raboud JM, Hart TA, Benoit A, Su D, Margolese SL, Rourke SB, Rueda S, Burchell A, Cairney J, Shuper P, Loutfy MR, Team OCSR (2016) Gender differences in severity and correlates of depression symptoms in people living with HIV in Ontario, Canada. J Int Assoc Providers AIDS Care 15:23–35

  4. Anthonypillai C, Gibbs JE, Thomas SA (2006) The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses. Cerebrospinal Fluid Res 3:1

  5. Arenas-Pinto A, Grund B, Sharma S, Martinez E, Cummins N, Fox J, Klingman KL, Sedlacek D, Collins S, Flynn PM, Chasanov WM, Kedem E, Katlama C, Sierra-Madero J, Afonso C, Brouwers P, Cooper DA, Group ISs (2018) Risk of suicidal behavior with use of Efavirenz: results from the strategic timing of antiretroviral treatment trial. Clin Infect Dis 67:420–429

  6. Bacon MC, von Wyl V, Alden C, Sharp G, Robison E, Hessol N, Gange S, Barranday Y, Holman S, Weber K, Young MA (2005) The Women's Interagency HIV study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol 12:1013–1019

  7. Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, Miotti P, Young M, Greenblatt R, Sacks H, Feldman J (1998) The women’s interagency HIV study. WIHS Collaborative Study Group. Epidemiology 9:117–125

  8. Bengtson AM, Pence BW, Mollan KR, Edwards JK, Moore RD, O'Cleirigh C, Eaton EF, Eron JJ, Kitahata MM, Mathews WC, Crane H, Mugavero MJ (2017) The relationship between Efavirenz as initial antiretroviral therapy and suicidal thoughts among HIV-infected adults in routine care. J Acquir Immune Defic Syndr 76:402–408

  9. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 57:125–133

  10. Best BM, Letendre SL, Koopmans P, Rossi SS, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, McCutchan JA, Morgello S, Simpson DM, Capparelli EV, Ellis RJ, Grant I, Group CS (2012) Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir. J Acquir Immune Defic Syndr 59:376–381

  11. Boeckle M, Schrimpf M, Liegl G, Pieh C (2016) Neural correlates of somatoform disorders from a meta-analytic perspective on neuroimaging studies. NeuroImage Clin 11:606–613

  12. Borghetti A, Baldin G, Capetti A, Sterrantino G, Rusconi S, Latini A, Giacometti A, Madeddu G, Picarelli C, De Marco R, Cossu MV, Lagi F, Cauda R, De Luca A, Di Giambenedetto S, Odoacre Study G (2017) Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients. AIDS 31:457–459

  13. Borghetti A, Baldin G, Lombardi F, Ciccullo A, Capetti A, Rusconi S, Sterrantino G, Latini A, Cossu MV, Gagliardini R, De Luca A, Di Giambenedetto S (2018) Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication. HIV Med

  14. Cassetti I, Madruga JV, Suleiman JM, Etzel A, Zhong L, Cheng AK, Enejosa J, Study ET (2007) The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials 8:164–172

  15. Ciesla JA, Roberts JE (2001) Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry 158:725–730

  16. Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ, Dickens C, Ferrier IN, Geddes J, Gilbody S, Haddad PM, Katona C, Lewis G, Malizia A, RH MA-W, Ramchandani P, Scott J, Taylor D, Uher R, Members of the Consensus M (2015) Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol 29:459–525

  17. Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, Chuck SL, Yale K, Liu HC, Warren DR, Ramanathan S, Kearney BP (2011) Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 25:F7–F12

  18. Cohen J, D'Agostino L, Wilson J, Tuzer F, Torres C (2017) Astrocyte senescence and metabolic changes in response to HIV antiretroviral therapy drugs. Front Aging Neurosci 9:281

  19. Cook JA, Cohen MH, Burke J, Grey D, Anastos K, Kirstein L, Palacio H, Richardson J, Wilson T, Young M (2002) Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women. J Acquir Immune Defic Syndr 30:401–409

  20. Cook JA, Grey DD, Burke-Miller JK, Cohen MH, Vlahov D, Kapadia F, Wilson TE, Cook R, Schwartz RM, Golub ET, Anastos K, Ponath C, Goparaju L, Levine AM (2007) Illicit drug use, depression and their association with highly active antiretroviral therapy in HIV-positive women. Drug Alcohol Depend 89:74–81

  21. Cook JA, Burke-Miller JK, Steigman PJ, Schwartz RM, Hessol NA, Milam J, Merenstein DJ, Anastos K, Golub ET, Cohen MH (2018) Prevalence, Comorbidity, and Correlates of Psychiatric and Substance Use Disorders and Associations with HIV Risk Behaviors in a Multisite Cohort of Women Living with HIV. AIDS Behav 22(10):3141–3154

  22. de Boer MG, van den Berk GE, van Holten N, Oryszcyn JE, Dorama W, Moha DA, Brinkman K (2016) Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice. AIDS 30:2831–2834

  23. Do AN, Rosenberg ES, Sullivan PS, Beer L, Strine TW, Schulden JD, Fagan JL, Freedman MS, Skarbinski J (2014) Excess burden of depression among HIV-infected persons receiving medical care in the United States: data from the medical monitoring project and the behavioral risk factor surveillance system. PLoS One 9:e92842

  24. Drevets WC, Price JL, Furey ML (2008) Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct 213:93–118

  25. Ellis R, Langford D, Masliah E (2007) HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci 8:33–44

  26. Elzi L, Erb S, Furrer H, Cavassini M, Calmy A, Vernazza P, Gunthard H, Bernasconi E, Battegay M, Swiss HIVCSG (2017) Adverse events of raltegravir and dolutegravir. AIDS 31:1853–1858

  27. Feinberg M (1993) The problems of anticholinergic adverse effects in older patients. Drugs Aging 3:335–348

  28. Fettiplace A, Stainsby C, Winston A, Givens N, Puccini S, Vannappagari V, Hsu R, Fusco J, Quercia R, Aboud M, Curtis L (2017) Psychiatric symptoms in patients receiving Dolutegravir. J Acquir Immune Defic Syndr 74:423–431

  29. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, Lu B, McColl D, Chuck S, Enejosa J, Toole JJ, Cheng AK, Study G (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354:251–260

  30. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF (2004) Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 44:499–523

  31. Giunta B, Ehrhart J, Obregon DF, Lam L, Le L, Jin J, Fernandez F, Tan J, Shytle RD (2011) Antiretroviral medications disrupt microglial phagocytosis of beta-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders. Mol Brain 4:23

  32. Harris M, Larsen G, Montaner JS (2008) Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS 22:1890–1892

  33. Hoffmann C, Welz T, Sabranski M, Kolb M, Wolf E, Stellbrink HJ, Wyen C (2017) Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med 18:56–63

  34. Ickovics JR, Hamburger ME, Vlahov D, Schoenbaum EE, Schuman P, Boland RJ, Moore J, Group HIVERS (2001) Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA 285:1466–1474

  35. Kapfhammer HP (2006) Somatic symptoms in depression. Dialogues Clin Neurosci 8:227–239

  36. Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB (1993) Sex and depression in the National Comorbidity Survey. I: lifetime prevalence, chronicity and recurrence. J Affect Disord 29:85–96

  37. Kheloufi F, Allemand J, Mokhtari S, Default A (2015) Psychiatric disorders after starting dolutegravir: report of four cases. AIDS 29:1723–1725

  38. Kim G, Decoster J, Huang CH, Chiriboga DA (2011) Race/ethnicity and the factor structure of the Center for Epidemiologic Studies Depression Scale: a meta-analysis. Cultur Divers Ethnic Minor Psychol 17:381–396

  39. Kohler JJ, Lewis W (2007) A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environ Mol Mutagen 48:166–172

  40. Lee JW, Aminkeng F, Bhavsar AP, Shaw K, Carleton BC, Hayden MR, Ross CJ (2014) The emerging era of pharmacogenomics: current successes, future potential, and challenges. Clin Genet 86:21–28

  41. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ (2008) Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65:65–70

  42. Liner KJ 2nd, Ro MJ, Robertson KR (2010) HIV, antiretroviral therapies, and the brain. Curr HIV/AIDS Rep 7:85–91

  43. Madeddu G, Menzaghi B, Ricci E, Carenzi L, Martinelli C, di Biagio A, Parruti G, Orofino G, Mura MS, Bonfanti P, Group CISAI (2012) Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study. AIDS 26:2412–2415

  44. Maki PM, Rubin LH, Cohen M, Golub ET, Greenblatt RM, Young M, Schwartz RM, Anastos K, Cook JA (2012) Depressive symptoms are increased in the early perimenopausal stage in ethnically diverse human immunodeficiency virus-infected and human immunodeficiency virus-uninfected women. Menopause 19:1215–1223

  45. Manda KR, Banerjee A, Banks WA, Ercal N (2011) Highly active antiretroviral therapy drug combination induces oxidative stress and mitochondrial dysfunction in immortalized human blood-brain barrier endothelial cells. Free Radic Biol Med 50:801–810

  46. Mangoni AA, Jackson SH (2004) Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 57:6–14

  47. Menard A, Montagnac C, Solas C, Meddeb L, Dhiver C, Tomei C, Ravaux I, Tissot-Dupont H, Mokhtari S, Colson P, Stein A (2017) Neuropsychiatric adverse effects on dolutegravir: an emerging concern in Europe. AIDS 31:1201–1203

  48. Mickaël C, Genolini C, Ecochard R (2013) KmLcov: k-means for longitudinal data with covariates. In. https://www.r-project.org/conferences/useR-2011/abstracts/290311-canouilmickael.pdf

  49. Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbell TB, Sax PE, Gulick RM, Na L, O'Keefe L, Robertson KR, Tierney C (2014) Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med 161:1–10

  50. Moore J, Schuman P, Schoenbaum E, Boland B, Solomon L, Smith D (1999) Severe adverse life events and depressive symptoms among women with, or at risk for, HIV infection in four cities in the United States of America. Aids 13:2459–2468

  51. Penafiel J, de Lazzari E, Padilla M, Rojas J, Gonzalez-Cordon A, Blanco JL, Blanch J, Marcos MA, Lonca M, Martinez-Rebollar M, Laguno M, Tricas A, Rodriguez A, Mallolas J, Gatell JM, Martinez E (2017) Tolerability of integrase inhibitors in a real-life setting. J Antimicrob Chemother 72:1752–1759

  52. Perez DL, Barsky AJ, Vago DR, Baslet G, Silbersweig DA (2015) A neural circuit framework for somatosensory amplification in somatoform disorders. J Neuropsychiatry Clin Neurosci 27:e40–e50

  53. Price JL, Drevets WC (2010) Neurocircuitry of mood disorders. Neuropsychopharmacology 35:192–216

  54. Rabkin JG (2008) HIV and depression: 2008 review and update. Curr HIV/AIDS Rep 5:163–171

  55. Rabkin J, Rabkin R (1997) Depression and HIV. Sidahora:19–22

  56. Radloff LS (1977) The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1:385–401

  57. Rathbun RC, Liedtke MD (2011) Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management. Pharmaceutics 3:745–781

  58. Revuelta-Herrero JL, Chamorro-de-Vega E, Rodriguez-Gonzalez CG, Alonso R, Herranz-Alonso A, Sanjurjo-Saez M (2018) Effectiveness, safety, and costs of a treatment switch to Dolutegravir plus Rilpivirine dual therapy in treatment-experienced HIV patients. Ann Pharmacother 52:11–18

  59. Robertson KR, Robertson WT, Ford S, Watson D, Fiscus S, Harp AG, Hall CD (2004) Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr 36:562–566

  60. Robertson K, Liner J, Meeker RB (2012) Antiretroviral neurotoxicity. J Neuro-Oncol 18:388–399

  61. Robertson K, Bayon C, Molina JM, McNamara P, Resch C, Munoz-Moreno JA, Kulasegaram R, Schewe K, Burgos-Ramirez A, De Alvaro C, Cabrero E, Guion M, Norton M, van Wyk J (2014) Screening for neurocognitive impairment, depression, and anxiety in HIV-infected patients in Western Europe and Canada. AIDS Care 26:1555–1561

  62. Rubin LH, Cook JA, Grey DD, Weber K, Wells C, Golub ET, Wright RL, Schwartz RM, Goparaju L, Cohan D, Wilson ML, Maki PM (2011) Perinatal depressive symptoms in HIV-infected versus HIV-uninfected women: a prospective study from preconception to postpartum. J Women's Health (Larchmt) 20:1287–1295

  63. Rubin LH, Radtke KK, Eum S, Tamraz B, Kumanan KN, Springer G, Maki PM, Anastos K, Merenstein D, Karim R, Weber KM, Gustafson D, Greenblatt RM, Bishop JR (2018) Cognitive burden of common non-antiretroviral medications in HIV-infected women. J Acquir Immune Defic Syndr 79(1):83–91

  64. Rubin LH, Springer G, Martin EM, Seaberg EC, Sacktor NC, Levine A, Valcour VG, Young MA, Becker JT, Maki PM, Neuropsychology Working Groups of the Women's InterAgency HIVS, the Multicenter ACS (2019) Elevated depressive symptoms are a stronger predictor of executive dysfunction in HIV-infected women than men. J Acquir Immune Defic Syndr 81(3)274–283

  65. Schweinsburg BC, Taylor MJ, Alhassoon OM, Gonzalez R, Brown GG, Ellis RJ, Letendre S, Videen JS, JA MC, Patterson TL, Grant I, Group H (2005) Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. J Neuro-Oncol 11:356–364

  66. Semple SJ, Patterson TL, Straits-Troster K, Atkinson JH, McCutchan JA, Grant I (1996) Social and psychological characteristics of HIV-infected women and gay men. HIV neurobehavioral research center (HNRC) group. Women Health 24:17–41

  67. Shah A, Gangwani MR, Chaudhari NS, Glazyrin A, Bhat HK, Kumar A (2016) Neurotoxicity in the post-HAART era: caution for the antiretroviral therapeutics. Neurotox Res 30:677–697

  68. Sherr L, Cluver L (2017) World health day focus on HIV and depression - a comorbidity with specific challenges. J Int AIDS Soc 20:21956

  69. Todd JV, Cole SR, Pence BW, Lesko CR, Bacchetti P, Cohen MH, Feaster DJ, Gange S, Griswold ME, Mack W, Rubtsova A, Wang C, Weedon J, Anastos K, Adimora AA (2017) Effects of antiretroviral therapy and depressive symptoms on all-cause mortality among HIV-infected women. Am J Epidemiol 185:869–878

  70. Underwood J, Robertson KR, Winston A (2015) Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease? AIDS 29:253–261

Download references

Acknowledgements

This work was supported by the Johns Hopkins University NIMH Center for novel therapeutics for HIV-associated cognitive disorders (P30MH075773) 2018 pilot award to Dr. Rubin. Dr. Williams effort was supported by R00DA044838. Data in this manuscript were collected by the Women’s Interagency HIV Study (WIHS). The contents of this publication are solely the responsibility of the authors and do not represent the official views of the National Institutes of Health (NIH). WIHS (Principal Investigators): UAB-MS WIHS (Mirjam-Colette Kempf and Deborah Konkle-Parker), U01-AI-103401; Atlanta WIHS (Ighovwerha Ofotokun, Anandi Sheth, and Gina Wingood), U01-AI-103408; Bronx WIHS (Kathryn Anastos and Anjali Sharma), U01-AI-035004; Brooklyn WIHS (Deborah Gustafson and Tracey Wilson), U01-AI-031834; Chicago WIHS (Mardge Cohen and Audrey French), U01-AI-034993; Metropolitan Washington WIHS (Seble Kassaye and Daniel Merenstein), U01-AI-034994; Miami WIHS (Maria Alcaide, Margaret Fischl, and Deborah Jones), U01-AI-103397; UNC WIHS (Adaora Adimora), U01-AI-103390; Connie Wofsy Women’s HIV Study, Northern California (Bradley Aouizerat and Phyllis Tien), U01-AI-034989; WIHS Data Management and Analysis Center (Stephen Gange and Elizabeth Golub), U01-AI-042590; Southern California WIHS (Joel Milam), U01-HD-032632 (WIHS I – WIHS IV). The WIHS is funded primarily by the National Institute of Allergy and Infectious Diseases (NIAID), with additional co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Cancer Institute (NCI), the National Institute on Drug Abuse (NIDA), and the National Institute on Mental Health (NIMH). Targeted supplemental funding for specific projects is also provided by the National Institute of Dental and Craniofacial Research (NIDCR), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Deafness and other Communication Disorders (NIDCD), and the NIH Office of Research on Women’s Health. WIHS data collection is also supported by UL1-TR000004 (UCSF CTSA), UL1-TR000454 (Atlanta CTSA), P30-AI-050410 (UNC CFAR), and P30-AI-027767 (UAB CFAR).

Author information

Dr. Rubin conceived the study idea and wrote the first draft of the manuscript with Drs. Xu and Williams, and Mr. Li. Dr. Xu and Mr. Li take responsibility for the integrity of the statistical analyses. All authors contributed to the writing of the manuscript and approved the final version of the article.

Correspondence to Leah H. Rubin.

Ethics declarations

Financial Disclosures

All authors have nothing to disclose.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic Supplementary Material

ESM 1

(DOCX 1280 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Williams, D.W., Li, Y., Dastgheyb, R. et al. Associations between Antiretroviral Drugs on Depressive Symptomatology in Homogenous Subgroups of Women with HIV. J Neuroimmune Pharmacol (2020) doi:10.1007/s11481-019-09899-2

Download citation

Keywords

  • HIV
  • Women
  • Depression
  • Heterogeneity
  • Antiretrovirals